Pemphigus foliaceous-like reaction in a patient with chronic myeloid leukemia treated with the tyrosine kinase inhibitors nilotinib and dasatinib


  • Conflicts of interest: FK has received grants, participated on advisory boards and is a speaker for Abbott, Amgen, Wyeth, Astellas, Centocor, Genentech, Stiefel, Eisai, Pfizer, Celgene, Merck and Novartis.

No abstract is available for this article.